Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
01:15pm, Tuesday, 04'th Mar 2025
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
09:46am, Monday, 03'rd Mar 2025
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
07:32am, Monday, 03'rd Mar 2025
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator
Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance
07:31am, Monday, 03'rd Mar 2025
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator
Stereotaxis Reports 2024 Full Year Financial Results
07:30am, Monday, 03'rd Mar 2025
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
08:03am, Tuesday, 25'th Feb 2025
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis
Stock Market Sleeps On Stereotaxis MAGiC CE Mark
10:41am, Friday, 14'th Feb 2025
Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. T
STXS Stock Gains Following the First Order for its GenesisX
09:21am, Tuesday, 04'th Feb 2025
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
04:05pm, Monday, 03'rd Feb 2025
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r
Stereotaxis Announces First GenesisX Robotic System Order
08:09am, Thursday, 30'th Jan 2025
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has receive
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
08:00am, Monday, 27'th Jan 2025
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
07:21am, Tuesday, 14'th Jan 2025
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
12:01pm, Monday, 16'th Dec 2024
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
07:25am, Monday, 09'th Dec 2024
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magne
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
08:45am, Monday, 02'nd Dec 2024
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest
